{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia5fup223u5akorx2ojll2zcz3oxjclvpmoxalxeiynh6lpw22pay",
    "uri": "at://did:plc:yhmwewfk3g3hhkrw2gf4ypna/app.bsky.feed.post/3mkjjzic7jfo2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifrrasmbestswcobydatamoajejaa5fs5dwuvvgji5wbyhkttzoky"
    },
    "mimeType": "image/png",
    "size": 1562386
  },
  "path": "/2026/04/27/how-europes-drug-pricing-policies-leave-american-families-paying-more-for-the-same-medicines/",
  "publishedAt": "2026-04-28T00:41:05.000Z",
  "site": "https://dissentwatch.com",
  "tags": [
    "#Column2",
    "Affordable Medications",
    "Alzheimer Disease Medication",
    "Alzheimer’s Drugs",
    "America First",
    "America First Policy",
    "American Families",
    "American Medical Innovation",
    "American Taxpayer Burden",
    "American Taxpayers Pharma",
    "Big Pharma",
    "Big Pharma Pricing",
    "Biotech Industry",
    "Brand Name Drug Costs",
    "Brand Name Drugs",
    "Cancer Drugs Pricing",
    "Cancer Treatment Costs",
    "Chronic Disease Costs",
    "Chronic Illness Treatment",
    "Clinical Trials",
    "Cost Of Prescription Drugs",
    "Diabetes Drug Prices",
    "Diabetes Medications",
    "Drug Cost Crisis",
    "Drug Import Debate",
    "Drug Manufacturer Pricing",
    "Drug Negotiation",
    "Drug Price Negotiation",
    "Drug Price Reciprocity",
    "Drug Price Transparency",
    "Drug Pricing",
    "Drug Pricing Disparity",
    "Drug Pricing Reform",
    "Drug Rebates",
    "Drug Rebates Discounts",
    "Economic Fairness",
    "Economic Fairness In Healthcare",
    "EU Pharmaceutical Regulation",
    "European Drug Policies",
    "European Price Controls",
    "European Union Drug Pricing",
    "Expensive Medications",
    "Fair Drug Pricing",
    "Fair Share Drug Pricing",
    "Family Medical Expenses",
    "Foreign Free Riding",
    "France Drug Prices",
    "Free Market Medicine",
    "General News",
    "Generic Drug Pricing",
    "Generics",
    "Germany Drug Prices",
    "Global Drug Development",
    "Global Drug Pricing Disparity",
    "Global Pharmaceutical Market",
    "Global Trade Policy",
    "Government Price Controls",
    "Health Economics",
    "Health Insurance Costs",
    "Health Policy",
    "Healthcare Affordability",
    "Healthcare Affordability Crisis",
    "Healthcare Costs",
    "Healthcare Equity",
    "Healthcare Policy",
    "healthcare reform",
    "Heart Disease Treatment",
    "Heart Medication",
    "High Drug Prices",
    "Innovation Funding",
    "Innovation Subsidy America",
    "Innovation vs Access",
    "Insurance Rebates",
    "Intellectual Property",
    "International Drug Prices",
    "International Drug Pricing",
    "Life Saving Drugs",
    "Lower Drug Costs Europe",
    "Lower Drug Prices",
    "Medical Breakthroughs",
    "Medical Innovation",
    "Medical Research Funding",
    "Medicare Drug Costs",
    "Medicare Part D",
    "Middle Class Healthcare",
    "National Drug Pricing Debate",
    "NATO Defense Analogy",
    "OECD Countries",
    "Out Of Pocket Costs",
    "Patent Protection",
    "Patent Protection Pharmaceuticals",
    "Patient Affordability",
    "Patient Financial Burden",
    "Patient Out Of Pocket Expenses",
    "Pharma Industry",
    "Pharma Industry Accountability",
    "Pharmaceutical Costs",
    "pharmaceutical industry",
    "Pharmaceutical Innovation",
    "Pharmaceutical Patents",
    "Pharmaceutical Reciprocity",
    "Pharmaceutical Subsidies",
    "Pharmaceutical Trade",
    "Pharmaceutical Trade Imbalance",
    "Pharmacy Costs",
    "Prescription Drug Affordability",
    "Prescription Drug Reform",
    "Prescription Drugs",
    "Prescription Medication Costs",
    "Prescription Savings",
    "Price Caps On Drugs",
    "Price Controls",
    "R&D Costs",
    "RAND Corporation Study",
    "Reciprocal Drug Pricing",
    "Reciprocal Trade",
    "Reciprocal Trade Agreements",
    "Reference Pricing",
    "Regulatory Drug Pricing",
    "Research and Development",
    "Rising Healthcare Costs",
    "Section 301 Trade Act",
    "Subsidizing Europe",
    "Subsidizing Foreign Healthcare",
    "Trade Act 1974",
    "Trade Act Section 301",
    "Trade Policy Pharmaceuticals",
    "Trump administration",
    "Trump Drug Policy",
    "Trump Pharmaceutical Strategy",
    "Trump Trade Policy",
    "US Drug Prices",
    "US Healthcare System",
    "US Pharma Subsidy",
    "US Pharmaceutical Market",
    "US vs Europe Healthcare",
    "Wealthy Nations Drug Costs",
    "White House Council of Economic Advisers"
  ],
  "textContent": "When a middle-class woman in Ohio picks up her husband’s heart medication at the pharmacy counter, the sticker shock hits hard: hundreds of dollars out of pocket, even with insurance. Yet the same drug, developed with American research dollars, sells for a fraction of that price across the Atlantic in countries like Germany or France. […]",
  "title": "How Europe’s Drug Pricing Policies Leave American Families Paying More For The Same Medicines"
}